Drug
ELOCTA
ELOCTA is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution1 total trials
Phase 1Safety & dosage
1(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 11 (100.0%)
Trials by Status
active_not_recruiting133%
completed267%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruiting
A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health
NCT04293523
completed
A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
NCT03055611
completedphase_1
BAY94-9027 PK Study Comparing to Another Long Acting Product
NCT03364998
Clinical Trials (3)
Showing 3 of 3 trials
NCT04293523
A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health
NCT03055611
A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
NCT03364998Phase 1
BAY94-9027 PK Study Comparing to Another Long Acting Product
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3